Stay updated with breaking news from Dun Yang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that their Founder, President and CEO, Dun Yang, PhD has been named as a 2022 In Vivo Rising Leader.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Chengdu, China (PRUnderground) March 1st, 2021 Anticancer Biosciences is applying its synthetic lethality expertise for better cancer therapies. The identification of novel antimitotic agents that do not lead to severe side effects is much significant in the present day oncology drug development. At the J. Michael Bishop Institute of Cancer Research (MBICR), China’s world-leading cancer research Centre, there are many advanced research initiatives in this context. A recently published study from our Natural Product Drug Discovery Group (NPDD) highlights a novel screening method in uncoveri...
Press release content from Business Wire. The AP news staff was not involved in its creation. Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline February 8, 2021 GMT CHENGDU, China--(BUSINESS WIRE)--Feb 8, 2021-- Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m), it has already achieved positive animal data in its small molecule program targeting MYC overexpression. ...
Reportable, Inc.: Anticancer Bioscience Presenting at Biotech Showcase Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Anticancer Bioscience is participating in Biotech Showcase Digital 2021. The Company will showcase its pioneering approach to precision oncology, and how it is applying its synthetic lethality expertise for better cancer therapies. The Company has five distinct synthetic lethality programs in drug development. Click image a...